A study analyzing 740 early-stage NSCLC patients treated with SBRT found that Squamous Cell Carcinoma (SqCC) has a significantly higher rate of local failure compared to other histological subtypes. SqCCs are more resistant to SBRT, which may require treatment optimization based on histological subtype.
Researchers at the University of Alberta have developed a new technique that uses focused ultrasound and nanoparticles to enhance cancer biomarker detection in blood samples. This non-invasive method has been shown to be as accurate as traditional biopsies, with potential applications for personalized medicine.
A new class of NIR-absorbing biodegradable organic nanoparticles has been developed for the targeting and treatment of deep-tissue tumors. These molecules can be triggered by low-power lamp light, allowing for precise tumor-targeting therapy with minimal side effects.
Researchers at The Wistar Institute found TRAP1 increases tumor cell proliferation and invasion while providing a potential new therapeutic target for prostate cancer. TRAP1 overexpression combined with PTEN loss led to aggressive invasive prostate cancer in mice.
Scientists have created biocompatible nanoseeds that can be injected into tumors to deliver radioactive isotopes, reducing damage to surrounding tissue. This innovative approach has the potential to improve radiation therapy for cancer patients, particularly those with inoperable solid tumors.
Researchers developed a new way to identify aggressive prostate cancer patients by analyzing their tumor's genetic pathways. The study found three subtypes of prostate tumors, with one subtype showing high disease progression and poor clinical outcomes.
Researchers at Duke University Medical Center report a novel compound, tetraaryl cyclobutane (CB), that blocks testosterone from fueling prostate tumor growth in mice. The compound has a unique mechanism of action and may be effective against prostate tumors resistant to current anti-androgen drugs.
Researchers have discovered a 'smart' organic nanoparticle called PEARLs that uses heat and light to target and ablate tumours with greater precision. This innovation addresses two bottlenecks in photo-thermal therapy, enabling more effective treatment of cancer with minimal damage.
Researchers at Case Western Reserve University have discovered that analyzing image features from adjacent benign tissues to tumor areas can provide an early warning for patients at higher risk of biochemical recurrence. This study may lead to doctors making decisions sooner about follow-up therapies or more regular monitoring.
A University of California San Diego study describes a new imaging biomarker that enhances MRI to differentiate aggressive prostate cancer from low-grade or benign tumors. The technology, called restriction spectrum imaging (RSI), allows for non-invasive detection and prediction of tumor grade without biopsy.
A new University of Illinois study reveals that the shape of a tumor may play a significant role in determining whether cells can metastasize. The research found that curved edges and corners activate cancer stem cells, which are responsible for spreading cancer to other tissues.
Researchers developed a new technique using nanoparticles that deliver therapeutic payloads and glow green when cancer cells begin dying. This allows for early detection of treatment effectiveness, potentially improving patient outcomes and quality of life.
A new study by researchers at Fred Hutchinson Cancer Center suggests that precision oncology could be tailor-made for metastatic prostate cancer. A single metastasis within an individual patient provides consistent molecular information to guide therapy, and patients benefit from individualized treatment.
A new study found that African American men with low-grade prostate cancer produce less PSA and have significantly lower PSA density than Caucasian men. This could lead to inaccurate surveillance criteria and affect treatment decisions for African American patients.
Researchers at MD Anderson Cancer Center identified myeloid-derived suppressor cells (MDSCs) as a key player in advanced prostate cancer progression. Depletion of MDSCs and blocking specific signaling pathways showed promise in suppressing tumor growth, paving the way for potential therapeutic opportunities.
Researchers found that losing CD73 enzyme promotes tumor growth and progression in endometrial cancer by disrupting adenosine signaling, which normally regulates tissue function. The study provides new insights into the role of CD73 in cancer development.
Researchers have discovered a potential weapon against cancer by harnessing the power of a malaria vaccine. The vaccine targets a specific carbohydrate found in both placenta and cancer cells, resulting in the death of cancer cells. Testing on mice has shown promising results, with over 90% of tumors attacked successfully.
Researchers at Duke University have successfully packaged a widely used cancer drug into nanoparticles, more than doubling its effectiveness in mice. The new approach delivers the drug directly to tumors while reducing side effects and improving targeting, showing transformative results for patients.
A new study found that increased radiation dose offers no survival benefit for patients with low-risk prostate cancer. In contrast, men with medium- and high-risk cancers saw improved survival rates with higher doses.
Researchers found that intermittent dosing with rapamycin selectively breaks the cascade of inflammatory events triggered by cellular senescence, providing proof-of-principal for a new treatment paradigm. The study shows that once disrupted, it takes time for the inflammatory loop to reestablish, offering hope for a safer and more effe...
The Scripps Proton Therapy Center in San Diego is reporting exceptional results in delivering cancer treatment using pencil-beam scanning technology, enabling the treatment of a wide range of tumor sites. The center has treated patients with lung, brain, spinal column, and other tumors, offering greater precision and efficiency in radi...
Researchers at the University of Chicago have identified a cell-intrinsic cancer-causing pathway that disrupts T cell infiltration in melanoma, enabling tumors to evade immune surveillance. Disrupting this signaling pathway could help restore T cell access and enhance the potential of immune-mediated cancer treatment.
Research led by Kansas State University's Brad Behnke suggests that moderate exercise can enhance tumor oxygenation, potentially improving the effectiveness of cancer treatments. Moderate-intensity exercise has been shown to increase oxygen delivery to tumors, making them more susceptible to radiation therapy.
Researchers found that blocking immune-suppressing cells allows chemotherapy to destroy prostate tumors in mouse models, achieving near complete remission. This novel combination therapy may have broader applications for other cancer types due to its effectiveness against metastatic and unresponsive cancers.
Researchers found that vitamin D supplements slowed tumor growth and reduced inflammation in men with low-grade prostate cancer. The study suggests that vitamin D may improve treatment outcomes for these patients by reducing the need for aggressive treatments.
Researchers found that MED15 overexpression is associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors. MED15 may serve as a prognostic marker for HNSCC recurrence and as a therapeutic target in HNSCC patients suffering from recurrences.
Researchers developed a customized genetic construct using tiny DNA minicircles to detect cancer in mice. The technique uses a protein called secreted embryonic alkaline phosphatase, which is not produced in adults but is present in embryos.
Scientists have created a conjugate molecule that targets and suppresses prostate cancer growth in mice, using a near-infrared dye and MAO-A inhibitor. The compound NMI shows promise as a therapeutic and diagnostic tool for prostate and other cancers.
Researchers at CNIC identified the molecular mechanism regulating transport of Rac1 between nucleus and cytoplasm. Sustained presence of Rac1 in nucleus promotes nuclear deformation to facilitate cell migration through confined spaces. The study provides potential targets for future therapies.
A novel imaging technique called restriction spectrum imaging-MRI (RSI-MRI) has been developed to improve the accuracy of prostate cancer detection. RSI-MRI corrects for magnetic field distortions and focuses on water diffusion within tumor cells, providing a more refined sense of the tumor's extent.
Researchers at MD Anderson Cancer Center have identified a protein complex called CSN and its subunit CSN6 as a key factor in cancer development. The study found that inhibiting CSN6 can quickly destabilize the master cancer gene Myc, greatly impairing tumor growth and metastasis.
Conventional treatments such as surgery and radiotherapy are less effective in prostate cancer patients carrying BRCA mutations, resulting in lower survival rates. The study suggests that targeted therapy, like PARP inhibitors, may be a more suitable option for these patients.
A molecular breakthrough has identified a compound that can inhibit the activity of SRPK1, a molecule key to tumor formation and blood vessel creation. This process is essential for cancer cell survival and multiplication.
Prostate cancer cells hoard copper, and researchers have found a way to deliver a trove of copper along with a drug that selectively destroys the diseased cells. This combination approach could lead to improved treatments for late-stage disease.
A new study published in Endocrinology found that testosterone treatment increased the incidence of prostate carcinomas in rats. The research suggests that testosterone alone is a weak carcinogen in male rats and creates a hospitable environment for tumors to develop when combined with cancer-causing chemicals.
Researchers matched 25 patients' treatment outcomes with their tumor's RNA sequence, finding similarities that could aid diagnosis and predict effective treatment. The study suggests that RNA sequencing may be a useful tool to aid personalized medicine in prostate cancer.
A team of scientists found that losing p62 in surrounding cells enhances tumor growth and progression. The study suggests therapies targeting the tumor microenvironment may be as important as targeting the tumor itself.
Two new genes, FOXM1 and CENPF, linked to more aggressive prostate cancer have been discovered. A new approach in the treatment of these patients is being developed using computer algorithms and biomarkers.
A new method using existing ultrasound scanners allows doctors to accurately detect prostate cancer with much greater precision, reducing the need for painful biopsies. The technique saves money by eliminating costly biopsy analysis and can potentially eliminate biopsies altogether.
Researchers have discovered a feedback loop between IL-6 and microRNA-34a that promotes tumor cell mobility and metastasis. The loop involves the activation of STAT3, which represses miR-34a production and leads to increased tumor-promoting proteins.
Researchers found that injecting a virus directly into one melanoma tumor can induce a potent anti-tumor immune response, destroying both infected and non-infected tumors. This combination therapy overcomes the limitations of oncolytic virotherapy and checkpoint blockade.
Research suggests that walking at a brisk pace prior to diagnosis may improve prostate cancer outcomes by having more regularly shaped blood vessels. Men with faster walking paces had 8% more regularly shaped blood vessels compared to those with slower paces.
Researchers will investigate racial and ethnic differences in IRDS-positive tumors prevalent in African-Americans to improve outcomes for patients with treatment-resistant prostate cancer. The study aims to identify new management and treatment options for this aggressive disease.
A study led by Beth Israel Deaconess Medical Center researchers found that carbon monoxide can prevent tumor growth and amplify chemotherapy's effects, sparing healthy tissue. The findings suggest CO induces an 'anti-Warburg' effect, fueling cancer cell bioenergetics until metabolic exhaustion.
A new study found that men with a specific genetic mutation are more than 50% likely to die from prostate cancer if they're overweight or obese. The researchers analyzed data on 1,243 participants and discovered that obesity was linked to higher levels of insulin and growth factor receptors in tumors containing the mutation.
Researchers discovered that selective inhibition of nuclear export protein CRM1 can reactivate tumor suppressor proteins in cells, leading to cancer cell death. This approach shows promise for treating advanced prostate cancers.
Researchers found that geranylgeraniol suppressed human DU145 prostate carcinoma cell viability via cell cycle arrest at the G1 phase and apoptosis initiation. The compound also down-regulated HMG CoA reductase, a key enzyme in the mevalonate pathway.
A new three-gene biomarker can accurately predict which low-risk prostate cancers will become aggressive, helping doctors determine whether men need active surveillance or invasive treatment. The test has shown promising results in a retrospective study of 43 patients, and further clinical trials are planned.
A new GE technology uses pyruvate levels to detect prostate tumors in real time, providing a safe and non-invasive way to assess cancer progression. The technology has shown promising results in a clinical study of 31 patients with prostate cancer.
A study found that a walnut-enriched diet reduced prostate cancer formation by 18% and slowed tumor growth. The results suggest that using walnuts on a regular basis may be beneficial in deferring or preventing certain types of cancer, including breast cancer.
Researchers at Albert Einstein College of Medicine have found that nerves play a critical role in both the development and spread of prostate tumors. The study suggests that targeting the autonomic nervous system may lead to novel therapies for preventing and treating prostate cancer.
Researchers at Cedars-Sinai Medical Center have uncovered the crucial role of Caveolin-1 protein in prostate cancer tumor microenvironment. A decreased level of this protein in the stroma indicates worse prognosis and higher chance of disease relapse.
Researchers used next-generation sequencing to analyze DNA alterations in adjacent Gleason patterns of the same tumor. The study found that some aggressive prostate cancers have identical genetic markers, enabling better prediction of cancer progression and management.
Researchers have identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest a potential new approach to blocking metastasis in various cancers.
Scientists at the University of Michigan have decoded the molecular signals that enable cancer cells to spread throughout the body. By understanding how tumor cells recruit healing cells, researchers can now develop drugs to block these messages and prevent metastasis.
Researchers are working on a technique that can help identify and treat cancer tumors using manganese-enhanced magnetic resonance imaging (MEMRI). The goal is to guide and individualize treatment based on the presence of specific calcium channels in tumors.
Researchers at Massachusetts General Hospital identified a genetic signature associated with the risk of tumor recurrence or spread in men surgically treated for prostate cancer. The 32-gene index proved to be the most accurate method, predicting actual incidence of tumor recurrence (47%) and metastasis (14%) among high-risk patients.
A recent study found that tumor boards have a modest association with the types of treatments patients receive for certain cancers. For example, lung cancer and prostate cancer patients were more likely to receive higher-quality care when treated at hospitals with tumor boards. However, other types of cancer care remained unaffected by...
A new targeted prostate biopsy technique using magnetic resonance ultrasound fusion has been shown to improve diagnosis of prostate cancer and aid in selecting patients for active surveillance. The study found that the biopsies identified 90 out of 171 men with prostate cancer, highlighting its potential as a more accurate and efficien...
Researchers found that high levels of COUP-TFII can overcome a natural barrier to prostate cancer progression, allowing tumor cells to grow and spread throughout the body. The study suggests that COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis.